EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access

Effect of Adherence to Oral Semaglutide on Glycemic Control in People With Type 2 Diabetes Treated With Metformin: Protocol for an Open-Label Clinical Trial

Nynne Sophie Holdt-Caspersen iD, Claus Dethlefsen iD, Ole Hejlesen iD, Erik Christiansen iD, Stine Hangaard iD, Peter Vestergaard iD, Morten Hasselstrøm Jensen iD

JMIR Research Protocols · 2025

DOI: 10.2196/64899 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift JMIR Research Protocols, 2025. Verfasst von Nynne Sophie Holdt-Caspersen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Data Science, Novo Nordisk A/S, Aalborg, Denmark. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Metformin, Hypoglycemic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Treatment adherence by people with type 2 diabetes (T2D) is overall suboptimal, which can hinder glycemic control. Multiple adherence barriers have been identified, such as the dislike and fear of injections. Several of the recommended antidiabetic drugs are available in oral formulations, which may be a good alternative to injection therapy when possible. However, strict dosing instruction could pose adherence barriers; for example, oral semaglutide requires predose and postdose fasting and restricted water intake at dosing time. Currently, oral semaglutide is the only oral glucagon-like peptide-1 receptor agonist and has only been available for a few years; therefore, limited knowledge exists on adherence to it.

Objective

The aim of this study is to investigate the effect of adherence to oral semaglutide dosing instructions on glycemic control in people with T2D who are dysregulated on metformin and optionally a sodium-glucose cotransporter-2 inhibitor and naïve to oral semaglutide.

Methods

This prospective, noninterventional, open-label, clinical trial with a duration of 12 weeks will be conducted in Denmark. Eligible participants are adults (aged ≥18 years) with dysregulated T2D (hemoglobin A1c of 53-75 mmol/mol) currently treated with metformin and optionally a sodium-glucose cotransporter-2 inhibitor for whom the next natural step in the treatment is to add an antidiabetic drug to the treatment regimen. Potential participants are recruited through announcements on social media and digital mail sent to their official digital mailbox (e-boks). During the trial, 20 participants will be initiated on oral semaglutide and escalated in dosage in accordance with the label. Information on the participants’ behavior related to the dosing instructions will be collected using the following devices: a smartwatch to track activity and sleep time, a smart pill bottle to track dosing time, a smart bottle to track time and volume of water intake at dosing time, and a smartphone to take a photo of their breakfast to log time of breakfast. Glycemic control will be assessed using an unblinded continuous glucose monitoring sensor that the participants will wear. Participants are asked to report any cases of nausea or vomiting in terms of time of occurrence, duration, and severity. The primary endpoint is change from baseline to end-of-study time-in-range derived from continuous glucose monitoring data.

Results

The first participant visit was in April 2024. Three months of high frequency temporal data on adherence behavior will be collected, despite the relatively few expected participants included.

Conclusions

Participants may change their behavior due to awareness of being observed. Regardless, the knowledge gained from this trial might be integrated into a decision support system, providing people with diabetes with guidance on how to increase adherence and potentially improving glycemic control. Trial Registration ClinicalTrials.gov NCT06333080.; https://clinicaltrials.gov/study/NCT06333080 International Registered Report Identifier (IRRID) DERR1-10.2196/64899

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like PeptidesMetforminHypoglycemic AgentsGlycemic ControlMedication AdherenceHumansAdministration, OralBlood GlucoseProspective StudiesFemaleAdultMaleMiddle AgedDenmarkGlycated HemoglobinAgedGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

continuous glucose monitoringdosing instructionsmedication adherenceobservational studyoral antidiabetic drugoral semaglutide

Substanzen

Glucagon-Like PeptidesMetforminHypoglycemic AgentsBlood GlucoseGlycated HemoglobinGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Department of Data Science, Novo Nordisk A/S, Aalborg, Denmark.
  • Department of Health Science and Technology, Aalborg University, Aalborg, Denmark.
  • Department of Mathematical Sciences, Aalborg University, Aalborg, Denmark.
  • Department of Medical & Science, Novo Nordisk A/S, Søborg, Denmark.
  • Steno Diabetes Center North Denmark, Aalborg University Hospital, Aalborg, Denmark.
  • Department of Endocrinology, Aalborg University Hospital, Aalborg, Denmark.

ORCID-Profile: Nynne Sophie Holdt-Caspersen, Claus Dethlefsen, Ole Hejlesen, Erik Christiansen, Stine Hangaard, Peter Vestergaard, Morten Hasselstrøm Jensen

Zitieren

APA

Holdt-Caspersen, N. S., Dethlefsen, C., Hejlesen, O., Christiansen, E., Hangaard, S., Vestergaard, P., & Jensen, M. H. (2025). Effect of Adherence to Oral Semaglutide on Glycemic Control in People With Type 2 Diabetes Treated With Metformin: Protocol for an Open-Label Clinical Trial. JMIR Research Protocols. https://doi.org/10.2196/64899

Vancouver

Holdt-Caspersen NS, Dethlefsen C, Hejlesen O, Christiansen E, Hangaard S, Vestergaard P, et al. Effect of Adherence to Oral Semaglutide on Glycemic Control in People With Type 2 Diabetes Treated With Metformin: Protocol for an Open-Label Clinical Trial. JMIR Research Protocols. 2025. doi:10.2196/64899

BibTeX
@article{HoldtCaspersen2025,
  author = {Holdt-Caspersen, Nynne Sophie and Dethlefsen, Claus and Hejlesen, Ole and Christiansen, Erik and Hangaard, Stine and Vestergaard, Peter and Jensen, Morten Hasselstrøm},
  title = {Effect of Adherence to Oral Semaglutide on Glycemic Control in People With Type 2 Diabetes Treated With Metformin: Protocol for an Open-Label Clinical Trial},
  journal = {JMIR Research Protocols},
  year = {2025},
  doi = {10.2196/64899}
}
Kostenlos starten →